|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Malignant cells frequently evolve multiple mechanisms for suppressing tumor-specific responses, including the induction of suppressive pathways involving AhR and its metabolic byproducts in the tumor microenvironment that promote immune evasion and tumor progression.
|
31816350 |
2020 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Overall, our data demonstrated that FICZ, as an AhR agonist could induce the expression of tumor suppressor miRNAs, <i>miR-22, miR-515-5p,</i> and <i>miR-124-3p</i>; thus, FICZ might be regarded as a potential therapeutic agent for breast cancer treatment.
|
31606975 |
2020 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Furthermore, LSCs suppressed a set of FICZ-responsive AHR target genes that function as tumor suppressors and promoters of differentiation.
|
31519687 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
SIGNIFICANCE: These findings show that AHR may function as a tumor suppressor in childhood neuroblastoma, potentially influencing the aetiologic and therapeutic targeting of the disease.
|
31431462 |
2019 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Gene expression analysis in PDAC tumors (n = 63) showed a positive correlation between the expression of NOS2 and the tryptophan/kynurenine pathway genes, including indoleamine-2,3-dioxygenase 1 (IDO1) and several aryl hydrocarbon receptor (AHR)-target genes including NFE2L2 (NRF2), SERPINB2, IL1b, IL6 and IL8, which are implicated in pancreatic cancer.
|
31609478 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We conclude that the AhR is a tumor suppressor-like gene in GBM; future studies are required to investigate whether the AhR could be a potential drug target for treating patients with GBM who express this receptor.
|
31171720 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
However, the AhR can also inhibit cellular proliferation in a ligand-dependent manner and act as a tumor suppressor in mice, thus may be a potential anticancer target.
|
30953668 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
<i>AHR</i> and <i>CYP1B1</i> mRNA levels were associated with the poor clinical prognosis markers tumour grade, lymphovascular invasion, cell proliferation and lymph node metastasis.
|
30899591 |
2019 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In this sub-group, total and nuclear AhR expression had an even stronger prognostic impact in patients with low RIP140-expressing tumors.
|
30813617 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A strong body of evidence indicated that AhR is implicated in cell proliferation and apoptosis, immune metabolism and other processes, which further affected tumor growth, survival, migration, and invasion.
|
31433724 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39.
|
30962630 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Expression of the aryl hydrocarbon receptor (AhR) has been described in various tumor entities from different organs.
|
31212758 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The aryl hydrocarbon receptor (AHR) is a ligand-activated signaling molecule which controls tumor growth and metastasis, T cell differentiation, and liver development.
|
30204910 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, AhR represents an attractive target to inhibit redox homeostasis and modulate the tumor promoting microenvironment of basal-like and BRCA1-associated BC.
|
30733286 |
2019 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Furthermore, VRCZ per se stimulates aryl hydrocarbon receptor (AhR) and upregulates COX-2, which is a pivotal enzyme for the promotion of UV-associated tumors, in an AhR-ARNT dependent manner of the classical (genomic) pathway.
|
29568008 |
2018 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry revealed the presence of AhR protein in both tumor cells (nucleus and/or cytoplasm) and the tumor microenvironment (including endothelial cells and lymphocytes).
|
29320557 |
2018 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Correction: Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma.
|
30701034 |
2018 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Emerging data have shed light on an unexpected role of the ligand-activated transcription factor aryl hydrocarbon receptor (AhR) in transducing the tumor immune escape function imparted by IDO1 and TDO2.
|
29254698 |
2018 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Aryl hydrocarbon receptor, a tumor grade‑associated marker of oral cancer, is directly downregulated by polydatin: A pilot study.
|
30015848 |
2018 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Therefore, targeting AHR or its downstream pathways could provide a novel approach to limit biomass production in MYC-driven tumors.
|
30254109 |
2018 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Therefore we examined the status of the AHR and its signalling molecules in human meningioma by using tumor biopsy samples and autopsy control meninges.
|
29302888 |
2018 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Finally, we suggest a potential therapeutic approach by targeting AHR in nerve tumors.
|
29351992 |
2018 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This review discusses the role of the AhR in tumor immunity and its potential mechanism of action in the tumor microenvironment.
|
29487603 |
2018 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
However, other studies have suggested that, under some circumstances, the AHR can oppose tumor aggression.
|
29735912 |
2018 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
AFP 464, which has a unique mechanism of action by activating aryl hydrocarbon receptor (AhR) signaling pathway, decreased tumor size, and growth rate in the estrogen dependent, Tamoxifen-sensitive spontaneous M05 mouse model.
|
28206673 |
2017 |